← SynDRA
TIZATERKIB
SynDRA canonical compound SYN0039898 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | MAPK1 |
|---|
| Mechanism of action | erk1 and erk2 phosphorylation inhibitor |
|---|
| Indication | non-small cell lung cancer (nsclc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK1 INHIBITOR
- erk1 and erk2 phosphorylation inhibitor
Cross-references
Synonyms
- ATG-017
- ATG017
- AZ-13820216
- AZ13820216
- AZD-0364
- AZD0364
- AZD 0364
- ATG 017
- VO9KX45QIQ
- RefChem:190188
- ERK1/2 Inhibitor ATG-017
- MFCD31631580
- TIZATERKIB [INN]
- Tizaterkib (USAN/INN)
- UNII-VO9KX45QIQ
- TIZATERKIB [USAN]
- orb1309958
- SCHEMBL18839079
- SCHEMBL29395978
- GTPL11674
- C24H24F2N8O2
- EX-A1812
- AZD-0364?
- BDBM50505988
- NSC808790
- AKOS037648851
- AT10135
- EBC-512220
- NSC-808790
- AC-36188
- BA166426
- BS-15828
- HY-111483
- CS-0042190
- D12921
- T10429
- LHZ
- (6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one
- ATG-017 hemiadipic acid
Look up TIZATERKIB in the interactive SynDRA portal →